Analysed ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) News Sources
Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge?
08-04-2026
yahoo.com
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know
08-04-2026
fool.com
How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 Targets
08-04-2026
yahoo.com
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
07-04-2026
yahoo.com
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
31-03-2026
yahoo.com
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
28-03-2026
yahoo.com
Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data
23-03-2026
yahoo.com
What is the current price of ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ)?
The current price of ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) is $24.12.
ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) absolute price change since previous trading day?
The absolute price change of ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) since the previous trading day is $-0.09.
ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) percentage price change since previous trading day?
The percentage price change of ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) since the previous trading day is -0.3717%.
What is the most recent average sentiment score for ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ)?
The most recent average sentiment score for ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) is 79 out of 100.
What is the most recent average sentiment for ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ)?
The most recent sentiment for ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ) is .
SEC-8K** Filing Available For ARCUTIS BIOTHERAPEUTICS INC (ARQT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.